Bind and Amgen in $180M cancer drug research deal

Home › Bind and Amgen in $180M cancer drug research deal

Drug developer Bind Biosciences said Tuesday that it will study potential cancer treatments with biotechnology company Amgen Inc.

05.10	Tropical Storm Milton Public Advisory Number 2
05.10	Hurricane Kirk Graphics
05.10	Hurricane Kirk Forecast Discussion Number 26
05.10	Tropical Storm Milton Graphics
05.10	Hurricane Kirk Wind Speed Probabilities Number 26
05.10	Hurricane Leslie Graphics
05.10	Hurricane Kirk Public Advisory Number 26
05.10	Summary for Hurricane Kirk (AT2/AL122024)
More »

je.st